Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

The history of treating disease with antibodies began in the 1800s after tetanus and diphtheria toxins were discovered, leading to the realization that immunity to the infections caused by these ...

Immunoglobulin G oligoclonal bands in CSF are highly prevalent in MS and CIS, with positive status associated with a significantly earlier age of disease onset.

If you have an immunodeficiency related to certain infections, inflammatory diseases, or autoimmune disorders, you may have heard about an infusion treatment called intravenous immunoglobulin, or IVIG ...

In a recent study published in Science Immunology, researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations. Study: ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...

BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...

The accelerated approval of iptacopan for IgAN was based on a reduction in proteinuria observed in the APPLAUSE-IgAN trial. The Food and Drug Administration (FDA) has granted accelerated approval to ...